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Abstract
Background: Emerging resistance of Pseudomonas aeruginosa within cystic fibrosis (CF) populations is attributed to antibiotic
pressure and spread of transmissible strains. We describe increasing resistance of P. aeruginosa isolates, resulting in the
identification of two multiresistant strains and their impact on morbidity. Methods: Susceptibility reports of all P. aeruginosa
isolates since 1998 in our unit were reviewed. Isolates were submitted for genomic finger-printing by pulsed-field gel
electrophoresis. Clinical measures and the consumption of treatment resources were compared between those harbouring resistant
organisms and those with sensitive strains. Results: Analysis of 407 reports from 43 patients revealed isolation of multiresistant
(MR) organisms increased during 1999. Those harbouring MR strains consumed more resources than non-MR. Strain typing
showed a new ‘Sheffield’ strain in seven patients (100% MR), and the ‘Liverpool’ strain in 10 patients (40% MR). Individuals
in these groups consumed significantly more resources than 23 patients with unique, susceptible strains (4% MR). Discussion:
Increasing resistance in isolates of P. aeruginosa may herald the arrival of a transmissible strain in CF Units which though
sometimes sensitive, may become multiply resistant and require more intensive treatment. We now segregate those with
transmissible strains from each other and from those with unique strains.
 2003 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Chronic respiratory infection, predominantly with
Pseudomonas aeruginosa, is the biggest cause of mor-
bidity and mortality cystic fibrosis (CF) w1x. Infection
is initially intermittent, asymptomatic and each episode
may involve different strain types. Early treatment w2x
may eradicate the organism and delay chronic infection
associated with mucoid forms w3x, which by secreting
alginate-like exopolysaccharides and growing as bio-
films, protect themselves from phagocytosis by the host
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and also from antibiotic therapy, making subsequent
eradication impossible (for review see Ref. w3x). Inflam-
mation caused by acute on chronic infection with P.
aeruginosa causes progressive lung damage and leads
to a relentless decline in lung function, ultimately
responsible for over 90% of deaths w1x.
Eradication is attempted each time the organism is
cultured with early detection achieved by regular sputum
culture w2x. Acute exacerbations of chronic infection are
treated with combination intravenous antibiotic therapy
(usually an aminoglycoside and beta lactam) w4x. Sup-
pressive therapy is employed either as maintenance
nebulised therapy (colistin w5x or tobramycin w6x) or by
three monthly, 2 weeks courses of antibiotics, or a
combination of both therapies w7x.
Intensive antibiotic therapy, particularly with monoth-
erapy w8x, is believed to lead to anti-microbial resistance
w3x. Various mechanisms leading to the development of
resistance during therapy have been described in P.
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aeruginosa w3,9x, however, resistant strains have been
identified in patients never exposed to antibiotics w8x.
Whilst cross infection with other organisms, notably
Burkholderia cepacia complex, has been well described
w10x, until recently person to person cross infection of
P. aeruginosa has been considered rare, and restricted
to close contacts associated with, summer camps, reha-
bilitation centres and between sibling pairs w11,12x.
However, there are recent reports from several clinics in
the UK of multiresistant P. aeruginosa w8,13–15x which
though phenotypically heterogeneous in their antibiotic
resistances have been shown by genomic fingerprinting
to be clonal, suggesting cross-infection or acquisition
from a common source. Segregation has been shown to
be effective in reducing the spread of B. cepacia
complex and has long been practised in Denmark to
reduce the spread of P. aeruginosa w7x. However, seg-
regation of P. aeruginosa positive patients on the basis
of strain types or multiresistance remains contentious.
The Sheffield Adult CF Unit was established at the
Northern General Hospital (NGH) in 1999. In that year,
patients from the local teaching hospital were transferred
followed by transfer of young adults from the Sheffield
Paediatric CF Centre in 2000. Almost immediately, we
noticed an increase in resistant P. aeruginosa. In mid
2001, one patient had sputum isolates referred to the
Edinburgh CF Microbiology Laboratory and Repository
and was found to carry the ‘Liverpool’ strain. Experi-
ence in the Liverpool Paediatric w8x and Adult Clinics
w13x suggests that this strain is both transmissible and
b-lactam resistant with implications for treatment and
possibly prognosis of patients. Furthermore, it cannot be
identified from a characteristic antibiogram since its
pattern of resistance to antibiotics may vary. We deter-
mined to screen our clinic for genotypic variants of P.
aeruginosa with a view to segregating patients with this
strain from those with unique strains.
2. Methods
The records of all patients attending the Sheffield
Northern General Hospital from 1998 to 2001 were
reviewed. Those who cultured P. aeruginosa from spu-
tum or cough swab samples on at least one occasion
were included. Where more than one sample growing P.
aeruginosa had been received in a given month from
one individual, only the first isolate was recorded.
Disc antibiotic susceptibility tests were performed on
mixtures of colonial morphotypes w16,17x resulting in a
single sensitivity result per specimen. Inoculum size and
interpretation of inhibitory zones were based on the
BSAC guidelines w18x. Susceptibility was determined
for the following antibiotic classes: quinolones (cipro-
floxacin), aminoglycosides (gentamicin, tobramycin,
amikacin) and b-lactams (aztreonam, ceftazidime, imi-
penemymeropenem wconsidered interchangeably in the
studyx, piperacillin, and piperacillin with tazobactam
(PT). Multiresistant (MR) organisms are defined as
‘resistant to all antibiotics in two or more antibiotic
classes’ w9x. Pan-resistant (PR) organisms are defined
as ‘resistant to all available antibiotics’ w9,19x.
Patients’ CF genotype and phenotype (described by
the presence of pancreatic insufficiency (PI) requiring
enzyme supplementation, CF related diabetes (DM)
requiring treatment, or liver disease (LD) on ultrasound
or with abnormal transaminases) was noted. Clinical
data including age, best routine lung function (forced
expiratory volume in the first second; FEV , and forced1
vital capacity; FVC, expressed as %predicted for age,
height and sex; %FEV , %FVC w20x), and weight-for-1
height as body mass index (BMI, kgym ) w21x were2
noted each year. All data were collected for the purposes
of this study in clinic by the CF Multidisciplinary Team
on the same equipment and excluded measurements
performed in the Pulmonary Function Laboratory or on
the ward during exacerbations.
Resource utilisation was assessed by the number of
clinic visits, the number of admissions and days in
hospital and the number of courses and days of intra-
venous (IV) antibiotics per year. Where patients had
attended the unit for only part of the year, their data
were proportionately scaled up to represent one full year
of attendance.
Single colonies of P. aeruginosa cultured from each
patient between October and December 2001 underwent
genomic fingerprinting (genotyping) by pulsed- field
gel electrophoresis (PFGE, CHEF-DRII system, BioRad
Hemel Hempstead, UK) after total DNA digestion with
endonucleases XbaI and SpeI and electrophoresis con-
ditions described previously w8x. Clonality was identified
based on the recommendations of Tenover et al. w22x
which requires that isolates belonging to the same strain
should not differ by four or more restriction fragments.
Clinical data were compared retrospectively for those
with MR vs. non-MR strains based on antibiograms
each year and by comparing ‘unique’ strains with those
from the two ‘epidemic’ strains (q.v.) identified by
PFGE.
2.1. Statistical analysis
Comparison of two groups (MR vs. non-MR) was by
Student’s t-test (for continuous parametric lung function
and weight) and Mann–Whitney U test (for discrete
clinic visits, in-patient stays, IV courses and non-para-
metric days in hospital on IV’s). Comparisons of three
groups (unique vs. strain 1 vs. strain 2 was by ANOVA
and Kruskal–Wallis tests, respectively. Paired data (2000
vs. 2001) were compared with Student’s paired t-test or
by Wilcoxon’s signed Rank Sum Test. Statistical signif-
icance was accepted when P-0.05. Data were organised
on Microsoft Excel and Astutes for Excel.
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Table 1
Summary data of patients attending the Sheffield Adult CF Clinic 1998–2001
1998 1999 2000 2001
Patients per year 18 24 33 45
Age (years) 28 (18–45) 27 (17–46) 27 (18–47) 25 (17–48)
DF508 alleles 73% 69% 77% 69%
DF508yDF508 53% 50% 52% 50%
PIa 74% 69% 75% 80%
DMb 21% 23% 16% 17%
LDc 33% 27% 26% 30%
%FEV d1 61 (14–101)% 61 (21–94)% 62 (21–104)% 68 (20–120)%
%FVCd 75 (18–112)% 78 (35–104)% 83 (41–118)% 86 (45–119)%
BMI kgym2 d 21.0 (16.7–26.1) 21.1 (14.6–26.1) 21.4 (15.3–26.6) 21.3 (16.0–27.3)
Sputum colonisation with
P. aeruginosa 67% 73% 81% 80%
S. aureus 67% 58% 78% 57%
B. cepacia complex 6% 4% 3% 4%
S. maltophilia 11% 23% 34% 7%
Pancreatic insufficient.a
Diabetes Mellitus.b
Liver disease.c
Best %predicted lung function and weight (Body Mass Index) that year as mean(range).d
3. Results
Fifty patients with CF confirmed by genotypic and
phenotypic criteria attended the clinic at least once
between January 1998 and December 2001. One died,
one left the clinic and three received double lung
transplants; their data are included up to these defining
events. Numbers attending each year with a summary
of their genotype, phenotype and clinical data are shown
in Table 1.
Over the 3 year period, P. aeruginosa was isolated
from 43y50 patients. The majority of isolates were
associated with chronic infections, though some were
eradicated by antibiotic treatment using nebulised colis-
tin with oral ciprofloxacin w2x or standard intravenous
therapy w4x. Bacteriological reports from 407 sputum
samples were analysed. 31% of isolates were fully
sensitive, 11% were resistant only to ciprofloxacin, 43%
had mixed resistance within the three antibiotic classes.
Analyses of resistance to individual antibiotics over time
were unremarkable, however, the proportion of isolates
resistant to all antibiotics within classes increased over
time from mid 1999. Multiresistance was very rare
before 1999 but peaked at 15% of isolates in September
2001. One strain was pan-resistant (PR) and lacked
sensitivity even to colistin or chloramphenicol. Those
who had isolated only sensitive strains (non-MR) had
substantially less class resistance in isolates compared
with those harbouring MR organisms (peak monthly
resistance of isolates to b-lactams 0% vs. 28%, amino-
glycosides 7% vs. 46% and ciprofloxacin 18% vs. 50%
for non-MR vs. MR carriers, respectively).
Of 43 patients with P. aeruginosa, 15 harboured MR
strains; one patient (8%) in 1998, five patients (26%)
in 1999, eight patients (32%) in 2000 and 10 patients
(27%) in 2001. Though not necessarily isolated from
every sputum culture, in 11 patients MR strains occurred
in multiple samples sometimes over years. Those
patients who grew at least one MR strain were compared
with those in the non-MR group. Only one patient was
present in 1998 and subsequent results refer to 1999–
2001 only. Their CF genotype, phenotype, severity and
use of resources are shown in Table 2. Although each
group was of similar age and range of clinical severity,
those in the MR group consistently utilised greater
resources.
From 40 patients attending in 2001 who had their P.
aeruginosa genotype analysed, 23 (57%) had unique
strains, 10 (25%) had strains indistinguishable from the
‘Liverpool’ strain and 7 (18%) shared a common strain
not previously seen, the ‘Sheffield’ strain. Four of 10
(40%) patients with the Liverpool strain and all with
the Sheffield strain had MR organisms. Only one patient
(4%) harboured a unique MR strain. One (the patient
first tested) harboured both Liverpool and Sheffield MR
strains. Fig. 1 shows PFGE profiles from isolates of the
Liverpool strain, Sheffield strain and five unique strains
from Sheffield patients (Lanes 2, 3 and 4–8,
respectively).
Based on the routine antibiograms reported by our
laboratory prepared on cultures in the last quarter of
2001, those subsequently shown to harbour the Liver-
pool strain were either fully sensitive or resistant to all
antibiotics except colistin. Those harbouring the Shef-
field strain showed resistance to ciprofloxacin but were
sensitive to colistin with MR isolates showing varying
resistance. 80–100% were resistant to gentamicin and
the b-lactams tested and 60% to tobramycin.
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Fig. 1. Chromosomal DNA digested with Spe1 and separated by
pulsed-field gel electrophoresis. Lane 1: lambda ladder (DNA size
marker), Lane 2: Liverpool strain, Lane 3: Sheffield strain, Lane 4–
8: unique strains from Sheffield patients.
Table 2
Comparison of patients harbouring MR and non-MR P. aeruginosa in 1999–2001 showing clinical parameters and resource utilisation per year
1999 2000 2001
MR Non MR MR Non MR MR Non MR
Patients 5 14 6 (1)a 20 11 26
Age (years) 25 (17–31) 27 (18–46) 25 (18–30) 27 (19–47) 24 (18–31) 26 (18–48)
DF508yDF508 40% 57% 63% 53% 70% 48%
PI 100% 79% 88% 79% 100% 81%
DM 20% 29% 25% 16% 30% 19%
LD 40% 29% 38% 26% 60% 26%
%FEV1 57 (19.9) 57 (23.4) 41 (17.6)b 63 (23.2) 62 (31.0) 68 (19.2)
%FVC 74 (21.4) 76 (20.7) 68 (26.1) 84 (19.3) 80 (25.6) 88 (13.2)
BMI kgym2 20.2 (2.1) 21.2 (3.0) 19.3 (2.1) 21.6 (2.6) 21.0 (3.6) 21.5 (2.4)
Clinic visits 10 (6–17)b 5 (1–10) 8 (1–21)b 4 (1–11) 7 (2–15)b 5 (1–9)
Admissions 3 (0–5) 0 (0–4) 3 (0–5)c 0 (0–4) 3 (0–8)c 0 (0–3)
Days admitted 35 (0–62) 0 (0–29) 28 (0–48)c 0 (0–48) 25 (0–72)c 0 (0–24)
IV courses 3 (0–7) 1 (0–3) 5 (0–7)c 0 (0–4) 4 (0–8)c 0 (0–3)
Days on IV’s 56 (0–106) 11 (0–35) 70 (0–111)c 0 (0–40) 50 (0–114)c 0 (0–41)
Legend as in Table 1; One patient MR post transplant has their data excluded from table; Lung function and weight as mean (S.D.), Visitsa
admissions, etc., as median (range); P-0.05 MR vs. non-MR; P-0.001 MR vs. non-MR.b c
Table 3 shows clinical parameters and resource util-
isation for the three groups: unique, Sheffield and
Liverpool strains in 2001. The Liverpool strain is sub-
divided to Liverpool MR and Liverpool non-MR sub-
groups. The Sheffield group had a higher proportion of
adverse phenotypic features (PI, DM, LD) and con-
sumed significantly more resources than the other
groups.
Five patients with the Sheffield strain and 11 with
unique strains attended in both 2000 and 2001 and are
compared in Table 4. Those with the Sheffield strain
were sicker and consumed more resources than the
older, healthier carriers of unique strains, and had a
greater requirement for resources in 2001 vs. 2000.
4. Discussion
In 1998, 20 patients were attending the NGH before
the formal establishment of the Adult CF Unit in
February 1999. Eight new patients arrived in 1999, nine
in 2000 and 17 in 2001. Those in 1999 were transferred
from a respiratory physician at the local Teaching
Hospital whilst the majority arriving in 2000 and 2001
came as transfers from the Children’s Hospital via the
CF Adolescent Clinic. A small number were transferred
from other centres outside Sheffield. The small size of
the clinic allowed one clinician (FPE) to review all
sputum results noting the changing resistance patterns
of P. aeruginosa as recommended by the Leeds group
w23x. Resistance was observed to be increasing in late
1999 and was documented by HRS in her student
project. Serendipity led to the identification of one
patient with the Liverpool strain.
Fifteen patients harboured MR organisms. As shown
in Table 2 the range of lung function and clinical
parameters are similar in MR and non-MR groups
suggesting neither severity of lung disease itself, nor
selective antibiotic pressure are necessary pre-requisites
to acquisition of P. aeruginosa. One patient with normal
lung function who last had IV antibiotics 3 years
previously had the multiresistant Sheffield strain on her
first isolate of Pseudomonas. She had been an in-patient
only once and did not attend clinic regularly.
Genotyping confirmed the predominance of isolates
unique to their host individuals. That only 1y23 of these
unique isolates is multiresistant is reassuring. However,
we are the second centre to report the highly transmis-
sible Liverpool strain w8,13x. Nine of the 10 patients
with the Liverpool strain were transferred from the local
CF paediatric clinic including the patient first tested and
one who had a double lung transplant at NGH and
continued her adult care at this centre (i.e. a post
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Table 3
Comparison of clinical status and resource utilisation of patients carrying Sheffield, Liverpool and unique strains of P. aeruginosa. Liverpool
strains are sub-divided to MR and non-MR
Unique Sheffield Liverpool L MR L Non-MR
Patients 18 6 7 4 3
Age (years) 27 (18–48) 25 (19–29) 24 (19–31) 25 (21–31) 22 (19–25)
DF508yDF508 65% 100% 70% 75% 67%
PI 43% 71% 50% 75% 33%
DM 13% 43% 0% 0% 0%
LD 26% 71% 30% 50% 17%
%FEV1 66 (21.3) 43 (15.7) 66 (28.9) 65 (40.3) 69 (7.6)
%FVC 89 (14.9)a 68 (17.8) 82 (22.2) 79 (30.0) 88 (6.3)
BMI kgym2 21.8 (2.6) 18.9 (2.0) 20.3 (3.0) 20.8 (4.1) 19.1 (1.0)
Clinic visits 6 (2–9)b 10 (6–15) 4 (2–15) 4 (2–15) 5 (2–6)
Admissions 0 (0–2)c 5 (3–8) 1 (0–8) 2 (0–8) 0 (0–3)
Days admitted 0 (0–24)c 50 (25–72) 12 (0–69) 16 (0–69) 0 (0–12)
IV courses 0 (0–3)c 5 (3–8) 1 (0–7) 2 (0–7) 0 (0–1)
Days on IV’s 0 (0–41)c 74 (33–114) 14 (0–104) 32 (0–104) 0 (0–14)
Legend as in Table 1; Lung function and BMI as mean (S.D.), Visits, admissions, etc., as median (range); P-0.05, ANOVA, P-0.05,a b
Kruskal–Wallis, PF0.001 Kruskal–Wallis. (all Unique vs. Sheffield vs. Liverpool).c
Table 4
Comparison of clinical status and resource utilisation of patients carrying the Sheffield strain of P. aeruginosa and attending in 2000 and 2001
compared with 11 patients carrying unique strains over the same period
Sheffield stains Unique strains
2000 2001 2000 2001
Age (years) 25 (21–28) 26 (22–29) 29 (20–47) 30 (21–48)
% FEV1 38 (29–44)a 38 (24–55) 59 (21–89) 56 (20–93
% FVC 64 (41–88) 65 (46–90) 82 (54–104) 80 (61–105)
BMI (kgym )2 19.1 (15.3–21.1)a 18.6 (16.0–21.3) 22.6 (18.3–26.6) 22.4 (18.6–27.3)
Clinic visits 8 (5–21)b 10 (7–15) 4 (3–7) 7 (2–9)c
Admissions 3 (2–5)b 5 (3–8)c 0 (0–2) 1 (0–2)c
Days admitted 35 (15–48)b 62 (36–72)c 0 (0–5) 2 (0–24)
IV Courses 4 (2–7)b 5 (3–8) 0 (0–4) 1 (0–3)
Days on IV Abx 40 (26–111)b 77 (33–114) 0 (0–14) 14 (0–41)c
Legend as in Table 1; Lung function and BMI as mean (S.D.), Visits admissions, etc., as median (range); P-0.05 t-test; P-0.01 Mann–a b
Whitney U (both Sheffield vs. Unique); P-0.05 Wilcoxon Signed Rank (2001 vs. 2000).c
transplant sputum sample). The tenth patient rarely
attended the Sheffield Unit but had previously attended
other adult centres in the UK.
The patients harbouring the Liverpool strain exhibited
similar clinical severity to those carrying unique strains,
however, the Liverpool MR group appeared to have a
worse clinical status than those with Liverpool non-MR
and (like those with the Sheffield (MR) strain q.v.)
consumed more resources; in contrast the Liverpool
non-MR individuals were at least as well as those in the
unique strain group and consumed fewer resources
(Table 4). It is not known whether the resistant or
sensitive forms of the Liverpool strain are the more
transmissible or whether it causes a clinical decline. It
is also possible that the development and use of molec-
ular fingerprinting techniques with more discriminatory
power than PFGE may reveal heterogeneity in what is
currently referred to as ‘the Liverpool strain’.
The ‘Sheffield’ strain has not previously been
described. Of seven patients (numbered for convenience
in order of attendance at this clinic) patients 1 and 2
have advanced disease with multiple admissions,
patients 3 and 5 come from the same paediatric clinic
and are in close social contact, patient 4 is sibling to
patient 1. Patient 6 is from the same paediatric clinic as
3 and 5 and has been an in-patient at the same time as
patients 2, 3 and 5 in this hospital. Patients 1–5 regularly
attend the same designated clinic. Patient 7 is the
individual with the MR organism described earlier.
These data suggest that the Sheffield strain is transmis-
sible and has been transmitted within our Unit.
All patients with the Sheffield strain had MR organ-
isms, were sicker and required significantly more treat-
ment than individuals harbouring unique strains or
resistant or sensitive forms of the Liverpool strain (Table
3). The five patients studied in 2000 and 2001 remained
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stable but required increased in treatment over the 2
years (Table 4). It is not known if the Sheffield strain
has a predilection for sicker patients or causes more
rapid clinical decline.
A possible confounding factor in these figures is the
presence of other organisms. We have only one patient
with B. multivorans (genomovar II) who has a unique
strain of Pseudomonas and has required little treatment.
Prevalence of Stenotrophomonas maltophilia (cultured
at least once in an individual during the year) was
highest in 2000 (9y26 with Pseudomonas, reduced to
3y37 in 2001. Three patients in each of the MR and
non-MR groups cleared the organism over that time. It
is unlikely that either of these organisms affected the
data presented here.
Opportunities for CF individuals to acquire unique P.
aeruginosa strains from natural environments are ample
and difficult to avoid entirely. Acquisition of multires-
istant strains is associated with hospitalisation
w8,13,14,24x with transmission likely to be by direct
contact, coughing, and poor hygiene. In the Manchester
CF centre, prospective surveillance revealed that 22y
154 (14%) patients shared an epidemic strain distinct
from the Liverpool and Sheffield strains (w14x, authors
unpublished data). Interestingly, none of the B. cepacia
complex infected patients (who were segregated)
acquired the epidemic strain of P. aeruginosa suggesting
that this policy had also prevented person to person
spread of the latter w14x. Person-to-person spread of P.
aeruginosa was also suggested by failure to identify
epidemic strains in hospital environments during epi-
demic outbreaks w8,13,24,25x. Recently, however, air-
borne dissemination of the Manchester strain has been
identified w26x.
The clinical significance of harbouring multiresistant
P. aeruginosa is unclear with little evidence to suggest
that infected individuals do worse w9x, even after trans-
plantation w19x. Some clinics, which experienced spread
of multiresistant strains introduced cohort segregation,
based on sputum microbiology, to limit further spread
w24x. As the antibiotic susceptibility patterns of the
Liverpool strain are variable (Cheng et al. w8x) and
epidemic strains may or may not exhibit resistance,
reliance on antibiotic resistance per se may not identify
episodes of cross-infection w27x. Segregation based on
genotype is more reliable and further supported by
reports that epidemic strains may superinfect patients
already infected with other strains of P. aeruginosa w13x.
A worrying development is reported by McCallum et
al. of an epidemic strain colonising the lungs and
causing morbidity in both parents of a patient with CF.
Chromosomal analysis showed parents and daughter
harboured identical organisms w28x.
CF patients who harbour highly transmissible P. aeru-
ginosa strains have a greater treatment burden than
patients with CF who harbour unique strains; including
an increase in hospital in patient days w29,30x respiratory
exacerbations and intravenous antibiotic treatment days
w30x. These findings are confirmed in our study, sug-
gesting that these strains are more virulent, potentially
multiresistant and more difficult to treat and eradicate.
Spread of multiresistant P. aeruginosa also deprives
patients of one the major advances in the management
of CF lung disease, namely eradication of P. aeruginosa
by prompt antibiotic therapy on first isolation. A dis-
turbing feature of the Manchester outbreak is that
patients previously free of P. aeruginosa who acquired
the multiresistant epidemic strain as a result of cross-
infection become chronically infected despite prompt
antibiotic therapy w14x.
Segregation, however, brings logistic complications
and has social implications for CF affected patients,
their siblings, friends and partners w25x. Geddes w25x
has questioned whether the term ‘epidemic’ is appropri-
ate when describing P. aeruginosa, since it is unknown
to what extent cross infection is determined by charac-
teristics of the strain or by lapses in infection control.
Whilst genomic fingerprinting for strains has certainly
confirmed cross infection within (or between) clinics,
whether this is the best method of surveillance and how
often it should be performed, or how it should be funded
are questions not yet answered. Further, despite the
recent data w29,30x and our findings, just how much
cross infection contributes to morbidity and mortality
and whether surveillance is therefore justified on clinical
grounds remains debatable.
Our response to these observations has been to extend
our segregation policies for both in- and out-patients.
In-patients are managed in side rooms. The importance
of hand washing by staff is emphasised for those moving
between CF patients and hygiene on the ward includes
cleaning of equipment and prompt disposal of used
sputum pots. The patients themselves are encouraged
not to socialise on or off the ward and not to share
items of a personal nature. Patients with B. cepacia
complex or Methicillin Resistant Staphylococcus aureus
(MRSA) are admitted to a different ward to other CF
patients.
Out-patient clinics are run for (i.) non-Pseudomonas,
(ii.) MRSAycepacia, (iii.) unique Pseudomonas and
(iv.) SheffieldyLiverpool strains on different weeks. On
arrival patients are placed in a room and are seen by
each member of the team who rotate between rooms,
washing hands between patients. Whenever possible, the
patient waiting area is not used and patients are encour-
aged to arrive and depart promptly to minimise contact.
Pulmonary function and other equipment, work surfaces
etc. are wiped with alcohol-based tissues between
patients. Patients attending outside clinic hours are seen
in the morning and placed in separate rooms, again to
minimise contact with others who ‘drop in’ for review.
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Currently, with relatively small numbers of patients this
system works well.
The modes of acquisition and spread of P. aeruginosa
remain unclear. However, based on previous evidence
and the data presented in our study, microbiological
surveillance and segregation of P. aeruginosa-free from
those known to be infected are prudent strategies to
prevent cross-infection, particularly by multiresistant
strains. Whilst patients are usually aware that they have
a multiresistant organism, we have avoided talk of
‘epidemic’ strains because we remain uncertain of their
potential implications and do not wish to cause undue
concern. We have advised patients that the clinics have
been reorganised to reduce the risk of cross-infection.
We do not know how often we should screen individuals
attending the clinic or what to do with patients who
exhibit transient colonisation. We believe that genotyp-
ing should be performed on all first isolations of P.
aeruginosa to detect episodes of cross-infection, and on
isolates from patients attending the clinic for the first
time to identify carriage of known transmissible strains.
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